PIERI, LISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.315
EU - Europa 4.293
AS - Asia 881
SA - Sud America 52
OC - Oceania 47
AF - Africa 33
Totale 10.621
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.299
PL - Polonia 2.208
RU - Federazione Russa 825
IT - Italia 366
SG - Singapore 277
IE - Irlanda 267
SE - Svezia 263
HK - Hong Kong 260
CN - Cina 122
DE - Germania 78
FI - Finlandia 75
CH - Svizzera 74
IN - India 53
AU - Australia 45
BR - Brasile 41
GB - Regno Unito 37
VN - Vietnam 34
FR - Francia 27
KR - Corea 24
TR - Turchia 24
ID - Indonesia 23
AE - Emirati Arabi Uniti 20
JO - Giordania 20
UA - Ucraina 20
CA - Canada 15
AT - Austria 12
BE - Belgio 12
CI - Costa d'Avorio 12
ES - Italia 10
JP - Giappone 7
EG - Egitto 6
ZA - Sudafrica 6
NL - Olanda 5
CO - Colombia 4
PE - Perù 4
RO - Romania 3
AZ - Azerbaigian 2
BY - Bielorussia 2
EC - Ecuador 2
HR - Croazia 2
IR - Iran 2
KE - Kenya 2
NZ - Nuova Zelanda 2
SC - Seychelles 2
TN - Tunisia 2
TW - Taiwan 2
AL - Albania 1
AO - Angola 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
IM - Isola di Man 1
IQ - Iraq 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MU - Mauritius 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 10.621
Salva come PNG Salva come JPEG
Città #
Warsaw 2.208
Santa Clara 1.282
Fairfield 747
Ashburn 355
Woodbridge 329
Seattle 308
Chandler 279
Dublin 266
Houston 256
Wilmington 246
Cambridge 245
Hong Kong 204
Ann Arbor 148
Singapore 148
Altamura 109
Lawrence 108
Princeton 81
Florence 73
Bern 72
Boston 65
Jacksonville 52
Beijing 44
Mumbai 43
San Diego 37
Melbourne 33
Boardman 30
Buffalo 30
Dong Ket 30
Bremen 28
New York 26
Shanghai 25
Jakarta 23
Izmir 22
Moscow 22
Seoul 21
Medford 20
Abu Dhabi 19
Phoenix 16
Norwalk 15
Abidjan 12
Brussels 12
Helsinki 12
Kent 12
Vienna 12
Barcelona 10
Hillsboro 10
Rome 10
Sydney 10
Dearborn 9
London 9
Los Angeles 9
Andover 7
Toronto 7
Munich 6
Parnaiba 6
Pune 6
Yubileyny 6
Alexandria 5
Cagliari 4
Campi Bisenzio 4
Falls Church 4
Guangzhou 4
Milan 4
Montreal 4
Redwood City 4
Romainville 4
West Jordan 4
Blaine 3
Bovalino 3
Getzville 3
Kashiwa 3
Laurel 3
Newark 3
Noicattaro 3
Padova 3
Paris 3
Pesaro 3
Quartu Sant'Elena 3
Siena 3
São Paulo 3
Athens 2
Bari 2
Beverley 2
Bogotá 2
Brescia 2
Brest 2
Camaiore 2
Cantagallo 2
Cecina 2
Cheyenne 2
Cincinnati 2
Costa Mesa 2
Curitiba 2
Farra di Soligo 2
Gomel 2
Gragnano 2
Guayaquil 2
Huancayo 2
Johannesburg 2
Kharkov 2
Totale 8.350
Salva come PNG Salva come JPEG
Nome #
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 364
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 295
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 293
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 289
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 281
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 280
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 275
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 267
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 255
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 251
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 249
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 248
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 246
Chronic myeloproliferative neoplasms: a collaborative approach. 245
Imaging studies in extramedullary hematopoiesis of the spleen 240
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 239
Study of new molecular alterations on Philadelphia-negative chronic myeloproliferative neoplasms 233
MPN Score 200
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 187
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 170
Mutations and prognosis in primary myelofibrosis. 155
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 151
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 145
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 140
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients 136
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 136
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 135
Treatment options for essential thrombocythemia and polycythemia vera 133
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. 129
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 129
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 128
Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis 128
The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. 126
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 121
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 120
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 120
BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques 120
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. 120
Risk of second cancers in chronic myeloproliferative neoplasms. 120
Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. 118
Concomitant occurrence of BCR-ABL and JAK2V617F mutation. 118
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. 118
Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. 114
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. 112
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 111
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 110
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 109
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 108
Mastocitosi: approccio multidisciplinare a una patologia misconoscciuta 106
Rationale for combination therapies in myelofibrosis 106
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study. 105
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis 104
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. 104
Risk of second cancers in chronic myeloproliferative neoplasms 103
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results 99
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 99
Prognotic Impact of Mutations in Systemic Mastocytosis 98
Low bone mass and hypovitaminosis D in haemophilia: A single-centre study in patients with severe and moderate haemophilia A and B 96
Fractures needing orthopaedic surgery in haemophilic patients: long-term experience of a dedicated team at a single institution 96
Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. 95
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience 91
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 91
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. 87
The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics. 83
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 80
Masked polycythemia vera (mPV): results of an international study. 80
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. 80
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. 78
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 76
Policitemia Vera. per conoscerla meglio. 76
Is pharmacological thromboprophylaxis necessary in persons with haemophilia undergoing major orthopaedic surgery? 26
Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single Center 25
Impaired platelet function in Hermansky-Pudlak syndrome associated with novel mutations in HPS3, HPS6 and HPS8 genes 12
null 10
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients 7
Totale 10.730
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.474
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.474
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020502 0 0 0 0 0 0 0 0 197 122 155 28
2020/20211.083 103 114 42 154 66 96 55 89 101 121 73 69
2021/2022488 14 48 48 16 13 19 20 39 27 26 76 142
2022/20231.353 121 289 68 111 94 216 160 66 102 15 34 77
2023/2024519 16 46 76 22 46 72 17 110 10 31 46 27
2024/20253.075 90 319 210 478 1.063 522 71 121 201 0 0 0
Totale 10.730